We searched PubMed on Jan 21, 2014 (reviewed Nov 14, 2014), using the search terms “MEN1” OR “Multiple Endocrine Neoplasia 1” AND “neuroendocrine tumour” OR “NET”, and limited to full-text human clinical trials or reviews/meta-analyses that were written in English in the past 5 years. Highly regarded prior publications and relevant references from the articles identified by the literature search were also reviewed.
ReviewChallenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1
Section snippets
Challenges
The challenges in screening for MEN1 P-NETs are to establish methods that are affordable, safe, and standardised; sufficiently sensitive to detect tumours that require intervention; and can be performed with adequate frequency to detect the majority of rapidly growing tumours. The availability of genetic testing for MEN1 coding region mutations, which can be detected in more than 90% of patients, has facilitated the identification of individuals at risk of developing MEN1-associated tumours.1,
Challenges
Establishing accurate predictors of outcomes that would guide the clinical management of MEN1 P-NETs represents a major challenge. Tumour grading and staging have been useful predictors for survival and treatment outcomes in oncology, but their use in MEN1 P-NETs remains to be established. Non-MEN1 P-NETs are graded (G) into one of three tiers as G1, G2, and G3 indicating well-differentiated, intermediate-differentiated, and poorly-differentiated tumours, respectively, using proliferation
Challenges
The selection criteria and choice of surgical procedures vary in different centres, making it difficult and challenging to provide definitive guidelines for surgical treatment of P-NETs in MEN1 patients. The ideal treatment for a non-metastatic, single, P-NET is surgical excision, as this offers the only potentially curative treatment.6 However, this situation rarely arises in patients with MEN1 who will have multiple P-NETs—eg, gastrinomas and insulinomas are multiple in more than 95% and more
Challenges
The choice of optimal anti-tumour therapies for advanced P-NETs in MEN1 patients remains a challenge as such therapies have not formally been evaluated in MEN1 patients. Thus, over ten different treatments for advanced, metastatic P-NETs in MEN1 patients are available (figure 3), and the challenge is in selecting the most appropriate one for an individual patient, as none of the treatments is wholly effective and data for efficacy are generally only available from studies in non-MEN1 patients.
Conclusion
P-NETs are the major cause of disease-specific mortality in patients with MEN1; however, very few MEN1-specific studies have been undertaken to guide the management of these tumours. Thus, in the absence of robust data, clinicians rely on expert consensus guidelines and extrapolations from studies involving non-MEN1 P-NETs to determine management in MEN1 patients. The latter is particularly concerning because MEN1 P-NETs exhibit distinct characteristics from non-MEN1 P-NETs, such as smaller
Search strategy and selection criteria
References (93)
Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)
Mol Cell Endocrinol
(2014)- et al.
Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry
Gastroenterol Clin Biol
(2004) - et al.
Epidemiology of gastroenteropancreatic neuroendocrine tumours
Best Pract Res Clin Gastroenterol
(2012) Surgical treatment of pancreatic endocrine tumors in multiple endocrine neoplasia type 1
Clinics (Sao Paulo)
(2012)- et al.
The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1
Clinics (Sao Paulo)
(2007) - et al.
Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1
Dig Liver Dis
(2012) - et al.
Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study
Gastrointest Endosc
(2012) - et al.
Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors
Mod Pathol
(2012) Surgical treatment and prognosis of gastrinoma
Best Pract Res Clin Gastroenterol
(2005)- et al.
Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Etude des Néoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE)
Gastroenterology
(1999)